Aggression subtyping for improved insight and trea.. (AGGRESSOTYPE)
Aggression subtyping for improved insight and treatment innovation in psychiatric disorders
Start date: Nov 1, 2013,
End date: Oct 31, 2018
Aggression is a basic physiological trait with important roles throughout evolution, both in defence and predation. When expressed in humans in the wrong context, aggression leads to maladjustment, social impairment and crime. Despite this, knowledge about aggression aetiology is limited and current treatment strategies are insufficient. Contingent to a subdivision into impulsive and instrumental subtypes, we investigate the aetiology of maladaptive aggression in paediatric conduct disorders most strongly predisposing to pathological aggression, ADHD and conduct disorder, and in the general population. We employ highly innovative approaches in humans and animal models and maximize the output from the project by optimally balancing the use of large, existing data sets with new data acquisition. Through this, we build a knowledge chain from molecule to behaviour, investigating known and novel genes, gene-networks and their epigenetic interactions, and mapping their mode of action from the molecular via the cellular to the brain-circuit level. This is accompanied by highly powered analyses of the neural substrates of the aggression subtypes.Based on innovative bioinformatic multimodal data integration, our interdisciplinary research will lead to novel, accurate algorithms for reliable aggression prediction, which will be validated in existing longitudinal studies in children and tested for their predictive value in adult outcome. In addition to this approach towards prevention, we test promising non-pharmacological biofeedback for personalised treatment and prevention of overt aggression. For the identification of novel pharmacological compounds in aggression treatment, we introduce a new animal model, the zebrafish.The Aggressotype consortium is based on successful existing collaborations. It includes experts in childhood and adult psychiatry and research-intensive SMEs ensuring maximal dissemination, clinical implementation and business development opportunities.
Get Access to the 1st Network for European Cooperation